Bacillus coagulans is the probiotic species identified on the reviewed Neotonics label. One gummy supplies 500 million CFU. CFU estimates viable microorganisms, not their weight in milligrams. Published outcomes vary by strain, dose, population and endpoint; studies of another B. coagulans preparation do not prove that Neotonics produces the same result.
- Present in Neotonics
- Yes
- Amount disclosed
- 500 million CFU
- Serving
- 1 gummy
- Species identified
- Bacillus coagulans
- Strain identified
- Not on the reviewed label
- Part of 430 mg blend
- No; listed separately
- Neotonics clinical trial
- None documented in this library
What is Bacillus coagulans?
It is a spore-forming, lactic-acid-producing bacterium used in some foods and probiotic supplements. Spore formation can help a microorganism tolerate manufacturing and digestive conditions, but stability alone does not establish a health outcome. Modern taxonomy may label some strains Heyndrickxia coagulans; the product label uses Bacillus coagulans.
Why is it measured in CFU?
Colony-forming units estimate the number of viable cells capable of forming colonies under test conditions. NIH’s Office of Dietary Supplements explains that CFU is more informative for viable probiotics than total weight. A larger CFU number is not automatically better: health effects depend on the microorganism, strain, viable dose through shelf life, and use studied.
How much is in Neotonics?
The reviewed Supplement Facts panel lists 500 million CFU per one-gummy serving. It does not show a strain code. This amount is separate from the 430 mg proprietary botanical blend, so milligrams from that blend should not be assigned to the probiotic.
Species versus strain: why it matters
A species name is broader than a strain identifier such as MTCC 5856, Unique IS2 or GBI-30 6086. Probiotic properties can differ below the species level. NIH cautions that findings for one strain should not be extrapolated automatically to another. Without a strain on the reviewed Neotonics label, a study on a named strain provides background—not a direct match.
What human research says about digestive outcomes
A 2023 network meta-analysis of 81 randomized trials found that outcomes in irritable bowel syndrome differed among probiotic strains and mixtures; two named B. coagulans strains ranked favorably for abdominal pain. Individual trials have also investigated gas, bloating and functional dyspepsia. These studies used defined strains, clinical populations and often doses in the billions of CFU. They should not be converted into a treatment claim for an unidentified strain in a 500-million-CFU gummy.
Microbiome-related outcomes
A randomized trial of strain MTCC 5856 in healthy adults evaluated microbiota composition at 2 billion CFU daily. It supplies evidence that a particular strain can be studied for microbiome effects, but it does not demonstrate the same effect at Neotonics’ disclosed amount or with an unspecified strain.
What does the evidence say about skin?
Oral probiotics are being researched across skin conditions and healthy-skin endpoints, but reviews repeatedly emphasize heterogeneity in strains, populations and outcomes. No source reviewed here establishes that the B. coagulans in Neotonics improves wrinkles, reverses aging, or treats a skin disorder. The gut–skin axis is a research framework, not proof of a specific cosmetic result.
How does 500 million CFU compare with studied doses?
Some cited B. coagulans trials used roughly 2 billion CFU daily; a functional-dyspepsia pilot used a multi-species product totaling several billion CFU per day. This numerical comparison cannot establish that 500 million CFU is inadequate or sufficient. Strain, viability, formulation, population and endpoint all change the interpretation.
Safety and tolerability
Probiotics usually cause only minor effects such as temporary gas in healthy people, but safety data are strain- and population-dependent. Serious infections are rare and have occurred mainly in people who were severely ill or immunocompromised. Stop use and seek care for a significant or allergic reaction.
Who should ask a healthcare professional first?
- People who are immunocompromised, seriously ill, hospitalized, or using central venous access
- Anyone pregnant, nursing, taking medication, or managing a medical condition
- Parents considering a probiotic supplement for a child
What the research does not prove about Neotonics
It does not prove that this finished gummy treats IBS, bloating, dyspepsia, acne or another condition. It does not identify the strain, confirm CFU at expiration, or establish equivalence to a clinical preparation. Research on this ingredient provides context, but it does not establish the effect of the finished Neotonics formula.
Frequently asked questions
How much Bacillus coagulans is in Neotonics?
Does Neotonics identify the probiotic strain?
Is 500 million CFU a high dose?
What does CFU mean?
References
- NIH Office of Dietary Supplements. Probiotics: Health Professional Fact Sheet.
- Outcome-specific efficacy of probiotic strains in IBS: systematic review and network meta-analysis.
- MTCC 5856 and functional gas and bloating: randomized trial.
- MTCC 5856 and microbiota in healthy adults: randomized trial.
- Spore-forming probiotics in functional dyspepsia: pilot randomized trial.